Trial Outcomes & Findings for Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity? (NCT NCT02939742)
NCT ID: NCT02939742
Last Updated: 2026-06-30
Results Overview
Mean number of days participants remained admitted to the Neonatal Intensive Care Unit (NICU) during hospitalization following birth.
TERMINATED
PHASE2/PHASE3
33 participants
daily from birth of infant up to one year or discharge from the NICU, whichever occurred first
2026-06-30
Participant Flow
Participant milestones
| Measure |
Betamethasone
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
Saline Placebo
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
|---|---|---|
|
Overall Study
STARTED
|
17
|
16
|
|
Overall Study
COMPLETED
|
17
|
16
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?
Baseline characteristics by cohort
| Measure |
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Total
n=33 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
17 Participants
n=20 Participants
|
16 Participants
n=20 Participants
|
33 Participants
n=40 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Sex: Female, Male
Female
|
17 Participants
n=20 Participants
|
16 Participants
n=20 Participants
|
33 Participants
n=40 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=20 Participants
|
5 Participants
n=20 Participants
|
9 Participants
n=40 Participants
|
|
Race (NIH/OMB)
White
|
13 Participants
n=20 Participants
|
11 Participants
n=20 Participants
|
24 Participants
n=40 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
|
Region of Enrollment
United States
|
17 participants
n=20 Participants
|
16 participants
n=20 Participants
|
33 participants
n=40 Participants
|
PRIMARY outcome
Timeframe: daily from birth of infant up to one year or discharge from the NICU, whichever occurred firstPopulation: Neonates were assessed for this Outcome Measure.
Mean number of days participants remained admitted to the Neonatal Intensive Care Unit (NICU) during hospitalization following birth.
Outcome measures
| Measure |
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
|---|---|---|
|
Average Number of Days in the Neonatal Intensive Care Unit (NICU)
|
29.93 days
Interval 1.0 to 124.0
|
29.41 days
Interval 2.0 to 79.0
|
SECONDARY outcome
Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occured firstPopulation: Neonates were assessed for this Outcome Measure.
defined as ≥ 1 of the following: RDS (oxygen requirement, clinical diagnosis, and consistent chest radiograph), bronchopulmonary dysplasia (requirement for oxygen support at 30 days of life), severe IVH (grades III or IV), periventricular leukomalacia, blood culture-proven sepsis, necrotizing enterocolitis, or perinatal death (stillbirth or death before neonatal hospital discharge)
Outcome measures
| Measure |
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
|---|---|---|
|
Number of Participants With Composite Neonatal Morbidity
Respiratory Distress Syndrome (RDS)
|
8 Participants
|
6 Participants
|
|
Number of Participants With Composite Neonatal Morbidity
Bronchopulmonary Dysplasia
|
2 Participants
|
4 Participants
|
|
Number of Participants With Composite Neonatal Morbidity
Severe IVH
|
0 Participants
|
0 Participants
|
|
Number of Participants With Composite Neonatal Morbidity
Periventricular Leukomalacia
|
0 Participants
|
0 Participants
|
|
Number of Participants With Composite Neonatal Morbidity
Blood Culture-Proven Sepsis
|
0 Participants
|
0 Participants
|
|
Number of Participants With Composite Neonatal Morbidity
Necrotizing Enterocolitis
|
0 Participants
|
0 Participants
|
|
Number of Participants With Composite Neonatal Morbidity
Perinatal Death
|
1 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: daily from birth until discharge from the NICU or up to 1 year of age, whichever occurred first.Population: Neonates were assessed for this Outcome Measure.
Amount of time, expressed in days from birth, that the infant required supplemental oxygen of any form, including nasal cannula, positive airway pressure, or ventilatory support. Reported as the mean number of days participants required supplemental oxygen therapy or ventilatory support.
Outcome measures
| Measure |
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
|---|---|---|
|
Average Number of Days Requiring Supplemental Oxygen or Ventilatory Support
|
29.93 days
Interval 1.0 to 124.0
|
29.41 days
Interval 2.0 to 79.0
|
SECONDARY outcome
Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occurred firstPopulation: Neonates were assessed for this Outcome Measure
Will be quantified as either present or absent. RDS defined as: compatible symptoms with radiographic evidence of hyaline membrane disease or respiratory insufficiency of prematurity requiring ventilatory support for ≥ 24 hrs
Outcome measures
| Measure |
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
|---|---|---|
|
Number of Participants Who Developed Respiratory Distress Syndrome (RDS)
|
8 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occurred firstPopulation: Neonates were assessed for this Outcome Measure.
Will be quantified as either present or absent. Grade III IVH defined as ventricles enlarged by accumulating blood. Grade IV IVH defined as bleeding extending into brain matter around the ventricles.
Outcome measures
| Measure |
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
|---|---|---|
|
Grade III or IV Intraventricular Hemorrhage (IVH)
Grade III Intraventricular Hemorrhage (IVH)
|
0 Participants
|
0 Participants
|
|
Grade III or IV Intraventricular Hemorrhage (IVH)
Grade IV Intraventricular Hemorrhage (IVH)
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: daily up to 72 hours of lifePopulation: Neonates were assessed for this Outcome Measure.
confirmed by culture in the first 72 hours of life
Outcome measures
| Measure |
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
|---|---|---|
|
Number of Participants With Neonatal Sepsis
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occurred firstPopulation: Neonates were assessed for this Outcome Measure.
Will be quantified as either present or absent. Stage 2 NEC will be defined as mild to moderate systemic illness, absent bowel sounds, abdominal tenderness, pneumatosis intestinalis or portal venous gas, metabolic acidosis, decreased platelets. Stage 3 NEC will be defined as severely ill, marked distention, signs of peritonitis, hypotension, metabolic \& respiratory acidosis, disseminated intravascular coagulopathy, pneumoperitoneum if bowel perforation present.
Outcome measures
| Measure |
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
|---|---|---|
|
Number of Participants With Necrotizing Enterocolitis (NEC) Stage 2 or 3
Necrotizing Enterocolitis (NEC) Stage 2
|
0 Participants
|
0 Participants
|
|
Number of Participants With Necrotizing Enterocolitis (NEC) Stage 2 or 3
Necrotizing Enterocolitis (NEC) Stage 3
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: assessed daily up to 120 days after birth or discharge from hospital, whichever occurred firstPopulation: Neonates were assessed for this Outcome Measure.
defined as stillbirth or death before neonatal discharge
Outcome measures
| Measure |
Saline Placebo
n=16 Participants
Women admitted with PPROM who will receive intramuscular saline placebo, given as two injections 24 hours apart.
Placebo: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
|
Betamethasone
n=17 Participants
Women admitted with PPROM who will receive a second course of two betamethasone 12mg intramuscular (IM) injections given 24 hours apart.
Betamethasone: Betamethasone 12mg IM given every 24 hours for two doses
|
|---|---|---|
|
Number of Perinatal Death(s)
|
1 Participants
|
1 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: time from admission to delivery up to one year, or through study completiontime from diagnosis of PPROM from admission until delivery of neonate or until completion of the study
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: time from admission until maternal discharge from the hospital and up until 6 weeks postpartum, or through study completionChorioamnionitis will be defined as at least one temperature elevation above 38°C combined with at least two of the following signs: maternal or fetal tachycardia, uterine tenderness, foul smelling vaginal discharge, white blood count \> 18,000. Postpartum endometritis will be defined as postpartum temperature elevation above 38°C without other localizing sources of infection and with either uterine tenderness or foul-smelling lochia.
Outcome measures
Outcome data not reported
Adverse Events
Betamethasone
Saline Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place